• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Commun Biol . Influence of AAV vector tropism on long-term expression and Fc-γ receptor binding of an antibody targeting SARS-CoV-2

tetano

Editor, Senior Moderator
Commun Biol


. 2024 Jul 16;7(1):865.
doi: 10.1038/s42003-024-06529-3. Influence of AAV vector tropism on long-term expression and Fc-γ receptor binding of an antibody targeting SARS-CoV-2

Jannik T Wagner[SUP] 1 [/SUP], Sandra M Müller-Schmucker[SUP] 1 [/SUP], Wenjun Wang[SUP] 2 [/SUP], Philipp Arnold[SUP] 3 [/SUP], Nadja Uhlig[SUP] 4 [/SUP], Leila Issmail[SUP] 4 [/SUP], Valentina Eberlein[SUP] 4 [/SUP], Dominik Damm[SUP] 1 [/SUP], Kaveh Roshanbinfar[SUP] 5 [/SUP], Armin Ensser[SUP] 1 [/SUP], Friederike Oltmanns[SUP] 1 [/SUP], Antonia Sophia Peter[SUP] 1 [/SUP], Vladimir Temchura[SUP] 1 [/SUP], Silke Schrödel[SUP] 6 [/SUP], Felix B Engel[SUP] 5 [/SUP], Christian Thirion[SUP] 6 [/SUP], Thomas Grunwald[SUP] 4 [/SUP], Manfred Wuhrer[SUP] 2 [/SUP], Dirk Grimm[SUP] 7 [/SUP], Klaus Überla[SUP] 8 [/SUP]



Affiliations
Abstract

Long-acting passive immunization strategies are needed to protect immunosuppressed vulnerable groups from infectious diseases. To further explore this concept for COVID-19, we constructed Adeno-associated viral (AAV) vectors encoding the human variable regions of the SARS-CoV-2 neutralizing antibody, TRES6, fused to murine constant regions. An optimized vector construct was packaged in hepatotropic (AAV8) or myotropic (AAVMYO) AAV capsids and injected intravenously into syngeneic TRIANNI-mice. The highest TRES6 serum concentrations (511 µg/ml) were detected 24 weeks after injection of the myotropic vector particles and mean TRES6 serum concentrations remained above 100 µg/ml for at least one year. Anti-drug antibodies or TRES6-specific T cells were not detectable. After injection of the AAV8 particles, vector mRNA was detected in the liver, while the AAVMYO particles led to high vector mRNA levels in the heart and skeletal muscle. The analysis of the Fc-glycosylation pattern of the TRES6 serum antibodies revealed critical differences between the capsids that coincided with different binding activities to murine Fc-γ-receptors. Concomitantly, the vector-based immune prophylaxis led to protection against SARS-CoV-2 infection in K18-hACE2 mice. High and long-lasting expression levels, absence of anti-drug antibodies and favourable Fc-γ-receptor binding activities warrant further exploration of myotropic AAV vector-based delivery of antibodies and other biologicals.


 
Back
Top Bottom